Janssen’s plaque psoriasis treatment Tremfya was found to be superior to Novartis' Cosentyx in treating adults with moderate-to-severe cases of the condition, according to findings of a late-stage study.
The Phase III ECLIPSE trial showed that Tremfya (guselkumab) was more effective than Cosentyx at reducing the severity and area of the body affected by the condition, with 84.5% of patients achieving at least 90% improvement in their baseline Psoriasis Area Severity Index (PASI) score at week 48 compared with just 70% of those taking Cosentyx (secukinumab).
Commenting on the results, study investigator Richard Langley said: "The response-over-time curves show that maximum response rates with Tremfya are achieved after six months and are maintained over time through one year.”
He added that the data "confirm a slightly more rapid onset of response with Cosentyx, but importantly, in a chronic disease like psoriasis, these data provide new insights into comparative longer-term efficacy.”
Psoriasis is a chronic autoimmune condition that causes the rapid buildup of skin cells causing scaling on the skin's surface, often with inflammation and redness around the affected areas.
Tremfya was approved in Europe for plaque psoriasis in November last year, while Cosentyx won EU clearance in January 2015.